Friday, July 11, 2014 7:31:47 PM
Distribute this link to the public...
for education and advocacy purposes.
http://goo.gl/IrOYIX
The public can copy and paste / download / tweet the link / use information for letters to Congress.
The letters at your link are excellent ways to drive home to FDA and Congress this message: the current science shows there is no longer any reasonable excuse to delay reinstatement of the SPA. FDA must yield to the science or else they look silly, if not worse.
Every Amarin supporter could help Amarin by doing this:
(1) copy and paste the letters,
(2) edit the second (longer) one to FDA (change the date and add your signature block)
(3) edit the first one (first sentence to say "Enclosed is a letter to two FDA officials ...") and address it to your congressman and two senators (three letters),
(4) mail the FDA letter to Jenkins, Woodcock and Hamburg, and (5) fax the short letter with copies of the FDA letter to your congressman and senators.
Letters to Congress matter, especially if received in volume. Let's help Amarin and ourselves by acting, not just talking.
Dr. Margaret A. Hamburg, FDA/OC
Department of Health and Human Services
200 Independence Avenue, S.W.
Washington, D.C. 20201
Fax: (301) 847-3531
Email: margaret.hamburg@fda.hhs.gov
Dr. Janet Woodcock
Director CDER
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
Fax: (301) 796-9856
Email: janet.woodcock@fda.hhs.gov
Dr. John Jenkins
Director, Office of New Drugs
Building WO22, Room 6304
Silver Spring, MD 20993-0002
Phone: (301) 796-0700
Fax: (301) 796-9856
Email: john.jenkins@fda.hhs.gov
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
Lawmakers Push FDA To Clarify Special Protocol Assessment Rescissions
http://www.sofinnova.com/news_detail.php?id=595
Congress Contacts
Your Representatives... ALSO the following:
http://www.contactingthecongress.org/cgi-bin/newcommittee.cgi?site=ctc2011&lang=en&commcode=happrop
http://www.contactingthecongress.org/cgi-bin/newcommittee.cgi?site=ctc2011&lang=en&commcode=happrop_ag
http://www.contactingthecongress.org/cgi-bin/newcommittee.cgi?site=ctc2011&lang=en&commcode=sapprop
http://www.contactingthecongress.org/cgi-bin/newcommittee.cgi?site=ctc2011&lang=en&commcode=sapprop_ag
http://www.contactingthecongress.org/cgi-bin/newcommittee.cgi?commcode=hcommerce&site=ctc2011&lang=en&&address=&city=&state=DC&zipcode=&plusfour=
The creation of a thousand forests is in one acorn.
Recent AMRN News
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 12:00:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 09:31:21 PM
- Amarin Chairman & CEO Issue Letter to Shareholders • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM